Ghanty I, Perez-Palma E, Villaman C, et al. SCN9A should not be considered an epilepsy gene; Refuting a gene-disease association. Epilepsia. 2025;66(9):3516-3527.
Gomez K, Stratton HJ, Duran P, et al. Identification and targeting of a unique NaV1.7 domain driving chronic pain. Proc Natl Acad Sci U S A. 2023;120(32):e2217800120.
Waxman SG. NaV1.7: A central role in pain. Neuron. 2023;111(17):2615-2617.
Sutemieva JA, Sobenin DV. Voltage-gated sodium channels in pain: Which channels, which blockers, and where NaV1.7 fits. Prog Biophys Mol Biol. 2026;200:138-162.
Gando I, Williams N, Fishman GI, Sampson BA, Tang Y, Coetzee WA. Functional characterization of SCN10A variants in several cases of sudden unexplained death. Forensic Sci Int. 2019 Aug;301:289-298.
Hu D, Barajas-Martínez H, Pfeiffer R, Dezi F, Pfeiffer J, Buch T, Betzenhauser MJ, Belardinelli L, Kahlig KM, Rajamani S, DeAntonio HJ, Myerburg RJ, Ito H, Deshmukh P, Marieb M, Nam GB, Bhatia A, Hasdemir C, Haïssaguerre M, Veltmann C, Schimpf R, Borggrefe M, Viskin S, Antzelevitch C. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol. 2014 Jul 8;64(1):66-79.
Xue Y, Chidiac C, Herault Y, Gaveriaux-Ruff C. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models. Neurosci Lett. 2021 May 14;753:135844.